Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 404

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 404
---
 accredited investor. In September 2024, we issued an aggregate of 2,853 shares of Series C Preferred Stock, at a price of $1,000 per share, and 4,088 shares of Series C Warrants, resulting in aggregate gross proceeds to us of approximately $1.25 million. In December 2024, we issued warrants to purchase an aggregate of 4,203 shares of Common Stock, with an exercise price of $112.20 per share, which was the closing price of the Common Stock on Nasdaq on December 20, 2024 (as adjusted for the Reverse Stock Splits), to certain institutional investors. Such shares were issued in reliance upon the exemption from registration set forth in Section 4(a)(2) of the Securities Act. In January 2025, the Company issued additional warrants to purchase an aggregate of 8,193 shares of Common Stock, with an exercise price of $116.40 per share, which was the closing price of the Common Stock on Nasdaq on January 3, 2025, to an institutional investor as a condition to the exercise of Preferred Warrants held thereby. In April 2025, we issued an aggregate of 6,250 shares of Series D Preferred stock, at a price of $800 per share, initially convertible into 8,012,821 shares of Common Stock at $15.60 per share, resulting in aggregate gross proceeds to us of approximately $5 million. On June 5, 2025, we sold an additional 938 shares of Series D Preferred Stock for gross cash proceeds of $750,400 in an additional closing and on June 25, 2025, we sold an additional 2,315 shares of Series D Preferred Stock for gross cash proceeds of $1,852,000 in an additional closing. On July 18, 2025, we sold an additional 497 shares of Series D Preferred Stock for gross cash proceeds of $432,600 in an additional closing of the Fourth PIPE Financing. The issuance of these securities was made pursuant to 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, and the rules promulgated thereunder, to accredited investors. II-2 Item 16. Exhibits and Financial Statements Schedules. (a) Exhibits.

| Exhibit 
 Number  
 2.1     
 2.2     |     | Description                                                                                                                                                                                                                                                                                                                                                                       
 Business Combination Agreement, dated as of June 4,